The T2DM-CVD-CKD triad: Why SGLT2 inhibitors? | Latest news for Doctors, Nurses and Pharmacists | Cardiology - specialty.mims.com
8/11/2022 12:00:00 AM2 years 8 months ago
by Prof. Peter Grant University of Leeds, UK
by Prof. Peter Grant University of Leeds, UK
The cardiorenal benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors shown in patients with type 2 diabetes mellitus (T2DM) have led to trial...
The cardiorenal benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors shown in patients with type 2 diabetes mellitus (T2DM) have led to trials evaluating their effect in heart failure (HF) a… [+9613 chars]
full article...